Literature DB >> 2610738

Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma.

S Ollerenshaw1, D Jarvis, A Woolcock, C Sullivan, T Scheibner.   

Abstract

Vasoactive intestinal polypeptide (VIP) is a neuropeptide present in the nerve fibers of normal lungs, where it acts to relax bronchial smooth muscle. To determine its presence or absence in the lungs of patients with asthma, we examined lung tissue obtained at autopsy or lobectomy from five patients with asthma and nine without asthma. The avidin-biotin-peroxidase complex technique was used to stain tissue for immunoreactivity to VIP. At least 80 tissue sections from each patient were examined microscopically; the airway diameter ranged from 100 microns to 1.2 cm. Immunoreactive VIP was seen within nerves in more than 92 percent of the sections from the lungs of patients without asthma. No VIP was seen in any of 468 sections we could evaluate that were obtained from the lungs of patients with asthma. As a control for the nonspecific destruction of neuropeptides, immunostaining for substance P was also carried out. Abundant amounts of this neuropeptide were seen within nerves in tissue from the lungs of all patients. We conclude that in patients with asthma there is a loss of VIP from the pulmonary nerve fibers that may diminish neurogenically mediated bronchodilation. Whether this loss is a cause or a result of asthma is unclear.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2610738     DOI: 10.1056/NEJM198905113201904

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  28 in total

1.  Molecular mapping of epitopes involved in ligand activation of the human receptor for the neuropeptide, VIP, based on hybrids with the human secretin receptor.

Authors:  B Olde; A Sabirsh; C Owman
Journal:  J Mol Neurosci       Date:  1998-10       Impact factor: 3.444

Review 2.  The diverse effects of mast cell mediators.

Authors:  Colleen Hines
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

Review 3.  Pharmacotherapy and airway remodelling in asthma?

Authors:  P A Beckett; P H Howarth
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

4.  Transmission-ratio distortion and allele sharing in affected sib pairs: a new linkage statistic with reduced bias, with application to chromosome 6q25.3.

Authors:  Mathieu Lemire; Nicole M Roslin; Catherine Laprise; Thomas J Hudson; Kenneth Morgan
Journal:  Am J Hum Genet       Date:  2004-08-20       Impact factor: 11.025

Review 5.  Adenosine bronchoconstriction in asthma: investigations into its possible mechanism of action.

Authors:  W H Ng; R Polosa; M K Church
Journal:  Br J Clin Pharmacol       Date:  1990       Impact factor: 4.335

6.  Non-adrenergic, non-cholinergic neural activation stabilizes smooth-muscle tone independently of eicosanoid factors in guinea-pig isolated airways.

Authors:  A Lindén; A Ullman; C G Löfdahl; B E Skoogh
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

Review 7.  Treatment of bronchospastic disorders in the 1990s. What does the future hold?

Authors:  P G Gianaris; J A Golish
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

Review 8.  Natural catalytic antibodies.

Authors:  S Paul
Journal:  Mol Biotechnol       Date:  1996-06       Impact factor: 2.695

9.  Functional effects of phosphoramidon and captopril on exogenous neuropeptides in human nasal mucosa.

Authors:  C Châtelain; N Pochon; J S Lacroix
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

10.  VIP antagonists enhance excitatory cholinergic neurotransmission in the human airway.

Authors:  H Aizawa; H Inoue; M Shigyo; S Takata; H Koto; K Matsumoto; N Hara
Journal:  Lung       Date:  1994       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.